Samuel Bjork

Samuel Bjork is a Partner at Digitalis Ventures, an early-stage venture capital firm managing over $800 million, where he specializes in life sciences and healthcare technology investments. He focuses on backing early-stage founders addressing critical problems across the human and animal health ecosystems, serving as a board director for companies like Bonum Therapeutics, Elemental Machines, EpiBiologics, Judo Bio, and Terray Therapeutics. Bjork previously held board director and observer roles for several startups that achieved successful exits, including PetMedix, which was acquired by Zoetis, and Good Therapeutics, which was acquired by Roche. Before joining Digitalis Ventures, he worked as a consultant in the healthcare and clean energy practices at the Boston Consulting Group. He holds an A.B. in Chemistry from Harvard University and earned graduate degrees from both Cambridge University and Oxford University as a Marshall Scholar.